CN Patent

CN109152772B — 烟酰胺的口服药物组合物

Assigned to Conaris Research Institute AG · Expires 2021-09-28 · 5y expired

What this patent protects

本文描述了用于口服给予烟酰胺或烟酰胺和美沙拉嗪的组合的药物组合物，以及制备这种药物组合物的方法，以及使用它们的治疗方法。该组合物包含烟酰胺或烟酰胺和美沙拉嗪的组合的延迟立即释放和延迟延长释放制剂。

USPTO Abstract

本文描述了用于口服给予烟酰胺或烟酰胺和美沙拉嗪的组合的药物组合物，以及制备这种药物组合物的方法，以及使用它们的治疗方法。该组合物包含烟酰胺或烟酰胺和美沙拉嗪的组合的延迟立即释放和延迟延长释放制剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN109152772B
Jurisdiction
CN
Classification
—
Expires
2021-09-28
Drug substance claim
No
Drug product claim
No
Assignee
Conaris Research Institute AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.